Boston Scientific (BSX): Director received 556 shares
Christophe Pierre Weber, Director at Boston Scientific, reported a grant / award of 556 shares.
- 556
- Shares
- Traded
- Mar 2, 2026
- Filed
- Mar 5, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Dec 17, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
- Dec 24, 2025CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
- Dec 29, 2025CongressDisclosed purchase of BSX — reported range $15,001 - $50,000
- Jan 14, 2026Company filing · Form 8-K · Material agreementSigned an important agreement
- Jan 30, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
- Feb 2, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 2, 2026, Yoshiaki Fujimori informed Boston Scientific Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
- Feb 2, 2026Insider · 1 personInsiders: 2 sales (~$15.0M)
- Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
- Feb 10, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
- Feb 12, 2026Federal contract · $519K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $519K obligated to date
- Feb 18, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors (and 1 more item)“On February 18, 2026 the Board of Directors (the “ Board ”) of Boston Scientific Corporation (the “ Company ”), upon the recommendation of the Nominating and Governance Committee of the Board, increased the number of directors comprising the Board from ten to twelve, and appointed each of Catherine R. Smith and Christophe P. Weber to be a director of the Company, to hold office until the next annual meeting of…”
- Feb 26, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 1 more item)
What came next
- Mar 5, 2026Court · District Court, D. MassachusettsSecurities lawsuit filed: In re: Boston Scientific Corporation Securities Litigation
- Mar 5, 2026Court · District Court, D. MassachusettsSecurities lawsuit filed: Troike v. Boston Scientific Corporation
- Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
- Apr 22, 2026Company filing · Form 8-K · ResultsReported its results
- Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
- Apr 30, 2026Company filing · Form 8-K · Bylaws or charter, Shareholder voteChanged its bylaws, charter or fiscal year, and held a shareholder vote
- May 6, 20265% stakeFMR LLC reported a passive stake (13G) of 5.1%
- May 11, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
- May 19, 2026Insider · First insider buy since Dec 2024Director purchased ~$125K of BSX shares in the open market
- May 19, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
- May 20, 2026Insider · 3 peopleInsiders: 3 purchases (~$429K)
- May 29, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
- Jun 11, 2026FDARecall: FARADRIVE STEERABLE SHEATH CLEAR, used to facilitate access to the vasculature and into the chambers of the heart, Material Number 21M402, IFU Reference Number…
- Jun 11, 2026FDARecall: FARASTAR Ablation Generator EU, Pulsed Field Ablation Generator, Product ID 61M401; Percutaneous Cardiac Ablation Catheter
- Jun 11, 2026FDARecall: FARASTAR Ablation Generator EU, Pulsed Field Ablation Generator, Product ID 61M401; Percutaneous Cardiac Ablation Catheter
- Jun 11, 2026FDARecall: FARASTAR Pulsed Field Ablation Generator, Product ID M004PFCE61M401; Percutaneous Cardiac Ablation Catheter
- Jun 11, 2026FDARecall: FARASTAR PFA Generator, Product ID M004PFCE61M460; Percutaneous Cardiac Ablation Catheter
- Jun 11, 2026FDARecall: FARADRIVE STEERABLE SHEATH CLEAR OUS, used to facilitate access to the vasculature and into the chambers of the heart, Material Number M004PFCE21M402, IFU Refe…
- Jun 11, 2026FDARecall: FARADRIVE Steerable Sheath Clear IDE, used to facilitate access to the vasculature and into the chambers of the heart, Material Number 21C602, IFU Reference Nu…
- Jun 11, 2026FDARecall: FARADRIVE STEERABLE SHEATH (CLEAR) - US, used to facilitate access to the vasculature and into the chambers of the heart, Material Number M004PF21M402, IFU Ref…
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Boston Scientific
For Boston Scientific, OQRO holds 1 insider filing (SEC Form 4 or Form 144), 7 Congress trade reports, 2 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BSX page.
How this filing works
Explore the data
Common questions
Which Boston Scientific (BSX) insider traded, and how much?
Christophe Pierre Weber, Director at Boston Scientific, reported a grant / award of 556 shares. Not an open-market trade.
When did it happen, and when was it made public?
Traded: Mar 2, 2026. Filed: Mar 5, 2026. That is 3 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Boston Scientific recently?
For Boston Scientific, OQRO holds 1 insider filing (SEC Form 4 or Form 144), 7 Congress trade reports, 2 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days. They are listed on the BSX page.
Does this mean BSX stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Boston Scientific
- SEC Form 13F-HRNov 16, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
- USAspending.gov award recordOct 1, 2026
Everything OQRO holds on this company is on its BSX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
